$CTMX mention timeline

CytomX Therapeutics. Every tracked FinTwit mention of $CTMX, newest first. 12 mentions since the first on Jul 25, 2025. See the price chart.

March 2026 · 7 mentions

Mar 16
Jacob Plieth — $CTMX efficacy wanes, but varseta-M still looks good. Shares +64% now! Via @ApexOnco -> https://t.co/PLy2CGE6lr $JANX↗
Mar 16
Jacob Plieth — @STL_Biotech Yes, I think so. As I wrote before, it would have been unrealistic for ORR to remain near 30% $CTMX↗
Mar 16
Jacob Plieth — $CTMX https://t.co/nRu1j1vmSF↗
Mar 16
Jacob Plieth — So: $CTMX efficacy falls from 28% (n=18) to 20% (n=56) across all 3 doses. Efficacy for 2 highest doses falls from 31% (n=13) to 26% (n=39).↗
Mar 16
Jacob Plieth — My $CTMX expectations, from earlier this month↗
Mar 16
Adam Feuerstein ✡️ — $CTMX colon cancer ADC study update https://t.co/QGbBpyJ00E↗
Mar 4
Jacob Plieth — $CTMX, +660% in 12 months, approaches its masked ADC catalyst. Via @ApexOnco -> https://t.co/oQI1iQiV4N ( $JANX -58% in the same timeframe)↗

Dec 3
Jacob Plieth — $JANX ended -53%, $CTMX -11%. Here's yesterday's take from @ByMadeleineA at @ApexOnco https://t.co/5cQ4Xw32YM↗

Nov 17
Jacob Plieth — $JNJ just acquired Halda for $3.05bn. Earlier story from @BatirtzeAreitio -> https://t.co/7nxuN3Oykj $JANX $CTMX↗

Aug 13
Jacob Plieth — @NotthatkindofDr Oh, yes I see now. Thx, just catching up with this $CTMX https://t.co/BzFJplpmRX↗
Aug 13
Jacob Plieth — So all good still for $CTMX varsetatug masetecan (CX-2051)? Additional ph1 data by Q1 2026 is in line with January disclosure. What "recent social media posts" are they referring t…↗

Jul 25
Jacob Plieth — $JANX resurrects a TROP2 asset, and continues tinkering with CD28. Meanwhile, JANX007 & JANX008 data are a waiting game. Via @ApexOnco -> https://t.co/kqO2x7AYOv $CTMX↗